- Dyne Therapeutics has finished enrolling patients in the registrational expansion cohort of its Phase 1/2 ACHIEVE trial for zeleciment basivarsen in myotonic dystrophy type 1 (DM1).
- This moves the DM1 program into a pivotal stage that sets the timeline for Dyne’s next major regulatory filing and potential launch plans.
- Topline data from the ACHIEVE trial are expected in early 2027, supporting a planned U.S. Accelerated Approval submission.
For investors watching NasdaqGS:DYN, the ACHIEVE milestone adds a second late stage program alongside the Duchenne muscular dystrophy work that has drawn most of the attention so far. The stock recently closed at $18.41, with a return of 31.6% over the past year and 36.8% over the past 3 years, while the 5 year figure is down 11.5%.
This DM1 step gives Dyne Therapeutics a more clearly defined clinical and regulatory path in another rare neuromuscular disease where patients currently have no approved treatment options. With a stated timetable for pivotal data and a planned Accelerated Approval submission, investors can now track two separate programs with specific regulatory decision points identified over the next few years.
Stay updated on the most important news stories for Dyne Therapeutics by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Dyne Therapeutics.
2 things going right for Dyne Therapeutics that this headline doesn't cover.
Investor Checklist
Quick Assessment
- ✅ Price vs Analyst Target: At US$18.41, the stock trades about 52% below the US$38.25 analyst price target.
- ✅ Simply Wall St Valuation: Currently assessed as undervalued, trading 81.8% below the estimated fair value.
- ✅ Recent Momentum: The stock is up 5.4% over the last 30 days.
There is only one way to know the right time to buy, sell or hold Dyne Therapeutics. Head to Simply Wall St's company report for the latest analysis of Dyne Therapeutics's fair value.
Key Considerations
- 📊 Completion of ACHIEVE enrollment turns the DM1 program into a defined registrational path, so the stock now reflects two late stage rare disease assets instead of one.
- 📊 Watch the timing and content of FDA interactions around the planned Accelerated Approval filing, as well as any updates to cash runway and share count.
- ⚠️ Dyne currently reports no revenue and has recently diluted shareholders, so funding needs around extended trials and a potential launch are key risks to track.
Dig Deeper
For the full picture, including more risks and rewards, check out the complete Dyne Therapeutics analysis. Alternatively, you can visit the community page for Dyne Therapeutics to see how other investors believe this latest news will impact the company's narrative.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com